Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Schrader

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Hypertension (Dallas, Tex. : 1979)|February 27, 2008
Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunctionSophocles Chrissobolis, Sean P Didion, Dale A Kinzenbaw, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trialM Kaufmann, N Maass, S D Costa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)B Gerber, S Loibl, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Hypertension (Dallas, Tex. : 1979)|February 27, 2008
Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunctionSophocles Chrissobolis, Sean P Didion, Dale A Kinzenbaw, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trialM Kaufmann, N Maass, S D Costa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)B Gerber, S Loibl, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 2